MG1-MAGEA3 is also being investigated in combination with a PD-1 inhibitor, pembrolizumab, in patients with first standard therapy-resistant NSCLC (NCT02879760) or metastatic melanoma and cutaneous squamous cell skin cancer (NCT03773744). Here, MAGEA3 is linked to non-small cell lung carcinoma.